Category - Markets

Markets

Stifel cuts AnaptysBio to hold; PT to $74 from $124

Stifel downgraded AnaptysBio (NASDAQ:ANAB) to “hold” from “buy” and cut its price target to $74 from $124 after disappointing clinical results from a competing asthma drug.

June 21, 2019

Markets

HCW starts Iterum Therapeutics at buy; PT $17

H.C. Wainwright launched coverage of Iterum Therapeutics (NASDAQ:ITRM) with a “buy” rating and $17 price target. The stock closed at $6.60 on June 20.

June 21, 2019

Markets

SVB Leerink starts Axovant Gene Therapies at OP; PY $18

SVB Leerink initiated coverage of Axovant Gene Therapies (NASDAQ:AXGT) with an “outperform” rating and $18 price target. The stock closed at $5.79 on June 20.

June 21, 2019

Markets

BTIG cuts Verastem to Neutral; PT removed

BTIF downgraded Verastem (NASDAQ:VSTM) to “neutral” from “buy” and removed its previous price target of $8 after the company announced that president and CEO, Robert Forrester, was stepping down. The stock closed at $1...

June 20, 2019

Markets

Alliance Global starts Precipio at buy; PT $6.30

Alliance Global Partners launched coverage of Precipio (NASDAQ:PRPO) with a “buy” rating and price target of $6.30. The stock closed at $3.12 on June 19.

June 20, 2019

Markets

Ladenburg starts Armata Pharma at buy; PT $9

Ladenburg Thalmann initiated coverage of Armata Pharmaceuticals (NYSE American:ARMP) with a “buy” rating and price target of $9. The stock closed at $2.86 on June 18.

June 19, 2019

Markets

Janney starts Anavex Life Science at buy; fair value estimate $10

Janney Montgomery Scott launched coverage of Anavex Life Science (NASDAQ:AVXL) with a “buy” rating and fair value estimate of $10. The stock closed at $3.14 on June 17.

June 18, 2019

Markets

Janney starts Neurotrope at buy; fair value estimate $14

Janney Montgomery Scott launched coverage of Neurotrope (NASDAQ:NTRP) with a “buy” rating and fair value estimate of $14. The stock closed at $6.36 on June 17.

June 18, 2019

Markets

SVB Leerink ups Provention Bio PT to $17 from $5.50

SVB Leerink raised its price target for Provention Bio (NASDAQ:PRVB) to $17 from $5.50, following positive At-Risk trial results presented at the American Diabetes Association meeting last week. The stock closed at $11...

June 18, 2019

Markets

Roth starts Translate Bio at buy; PT $25

Roth Capital Partners initiated coverage of Translate Bio (NASDAQ:TBIO) with a “buy” rating and price target of $25. The stock closed at $10.08 on June 17.

June 18, 2019

Category - Markets

Stifel cuts AnaptysBio to hold; PT to $74 from $124

HCW starts Iterum Therapeutics at buy; PT $17

SVB Leerink starts Axovant Gene Therapies at OP; PY $18

BTIG cuts Verastem to Neutral; PT removed

Alliance Global starts Precipio at buy; PT $6.30

Ladenburg starts Armata Pharma at buy; PT $9

Janney starts Anavex Life Science at buy; fair value estimate $10

Janney starts Neurotrope at buy; fair value estimate $14

SVB Leerink ups Provention Bio PT to $17 from $5.50

Roth starts Translate Bio at buy; PT $25

General

More